Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Akershus University Hospital · Diakonhjemmet Hospital · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
802
total citations
- FWCI
- 52.37
- Percentile
- 100%
- References
- 32
Citations per year
Authors
57Topics & keywords
Topics
Keywords
- Biosimilar
- Infliximab
- Medicine
- Double blind
- Internal medicine
- Oncology
- Placebo
- Tumor necrosis factor alpha
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.